Sugi Predict

Sugi Predict / Compounds / SCHEMBL3351008

SCHEMBL3351008

SCHEMBL3351008

Cc1cc(Br)ccc1S(N)(=O)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDIA6 Q15084 1/20 0.51
▸ CA2 P00918 7/20 0.49
▸ CA1 P00915 5/20 0.49
▸ CA12 O43570 3/20 0.45
▸ CA9 Q16790 3/20 0.45
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ BRD4 O60885 1/20 0.40
▸ BRD1 O95696 1/20 0.40
▸ BRPF1 P55201 1/20 0.40
▸ BRPF3 Q9ULD4 1/20 0.40
▸ PTGES2 Q9H7Z7 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ CA7 P43166 1/20 0.38
▸ HCRTR1 O43613 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30200838 1.00 PDIA6 (0.51) PDIA6CA2CA1CA12CA9
SCHEMBL1346608 0.83 CA2 (0.49) CA2CA1CA12CA9CA4
SCHEMBL9474855 0.83 CA1 (0.51) CA2CA1L3MBTL1BRD4BRD1
SCHEMBL31195820 0.81 L3MBTL1 (0.59) CA2CA1L3MBTL1ALDH1A1BRD4
SCHEMBL2333956 0.81 L3MBTL1 (0.59) CA2CA1L3MBTL1ALDH1A1BRD4
SCHEMBL8404316 0.80 CA2 (0.50) PDIA6CA2CA1CA12CA9
SCHEMBL10178168 0.80 CA2 (0.50) PDIA6CA2CA1CA12CA9
SCHEMBL30200885 0.79 CA1 (0.49) CA2CA1L3MBTL1BRD4BRD1
SCHEMBL6012134 0.79 CA1 (0.49) CA2CA1CA12CA9L3MBTL1
SCHEMBL310277 0.79 CA1 (0.49) CA2CA1L3MBTL1BRD4BRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197387-A1 BCL-XL DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-19 — — US disclosed
CN-119977905-A Green synthesis method of saccharin and saccharin derivative 湖南科技大学 2025-05-13 — — CN disclosed
EP-4401729-A1 BCL-XL DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-24 — — EP disclosed
US-11999758-B2 Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer INVENTIVA (FR) 2024-06-04 — — US disclosed
CN-113039182-B Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment 伊文蒂瓦公司 2024-02-20 — — CN disclosed
US-11858927-B2 Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-01-02 — — US disclosed
US-11858927-B2 Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-01-02 — — US disclosed
WO-2023044046-A1 BCL-XL DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-23 — — WO disclosed
EP-3860990-B1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER INVENTIVA (FR) 2022-09-14 — — EP disclosed
EP-3939968-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME Medicinal Bioconvergence Research Center (KR) 2022-01-19 — — EP disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 — — US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 — — EP disclosed
US-20040116399-A1 Inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2004-06-17 — — US disclosed
US-6300352-B1 FOR THERAPY OF ASTHMA ASTRAZENECA AB (SE) 2001-10-09 — — US disclosed
CN-1257481-A Pyridine derivatives and pharmaceutical compositions containing them ASTRA PHARMA PROD (GB) 2000-06-21 — — CN disclosed
EP-0971892-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Astra Pharmaceuticals Limited (GB) 2000-01-19 — — EP disclosed
WO-1998042670-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRA PHARMACEUTICALS LTD. (GB) 1998-10-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD PDIA6 2176/4885CA2 1976/4885CA1 3580/4885
US-11999758-B2 Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer YAP1, TEAD2, YES1 PDIA6 3808/4885CA2 3706/4885CA1 4802/4885
US-20250197387-A1 BCL-XL DEGRADERS AND USES THEREOF XIAP, BCL2L1, BCL2L10 PDIA6 966/4885CA2 3825/4885CA1 2550/4885
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 PDIA6 896/4885CA2 236/4885CA1 1466/4885
US-11858927-B2 Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAP3K4, MAP4K1 PDIA6 2563/4885CA2 4640/4885CA1 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.